Relation of @entity5337 genotype to risk for XXXX after joint replacement surgery.

@entity1 @entity5337 @entity548 @entity49 @entity1150 @entity67191 @entity1229
BACKGROUND: A point mutation in coagulation factor V ( @entity67191 ) is associated with increased risk for @entity49 . However, limited information is available about the prospective risk for @entity1150 in specific high-risk clinical settings. OBJECTIVE: To determine whether the @entity5337 mutation is associated with an increased occurrence of @entity1150 in @entity1 undergoing hip or knee replacement surgery. DESIGN: Retrospective analysis of plasma samples obtained during six prospective clinical trials that compared different antithrombotic prophylaxis regimens in @entity1 undergoing hip or knee replacement surgery. SETTING: Inpatients at the University of Rochester Medical Center, McMaster University Medical Center, Hamilton Civic Hospitals, and the Genesee Hospital. @entity1 : 825 @entity1 hospitalized for hip or knee replacement surgery. MEASUREMENTS: Venographically diagnosed postoperative @entity1150 was correlated with factor V genotype. RESULTS: The @entity5337 mutation was not associated with a significantly increased risk for venographically detected @entity1150 . The absolute incidence of @entity1150 was 31% (95% CI, 15% to 47%) in @entity1 with the mutation and 26% (CI, 22% to 29%) in @entity1 without the mutation (relative risk, 1.2 [CI, 0.6 to 2.9]). The @entity5337 mutation was not significantly associated with @entity1150 in subgroups of @entity1 receiving @entity1229 or heparin. The incidence of clinical @entity548 was similar in @entity1 with (10%) and without (8%) the mutation. CONCLUSIONS: The @entity5337 mutation is not a significant risk factor for @entity1150 in this group of @entity1 . Current data do not justify routine preoperative screening for this mutation or intensified perioperative prophylaxis in @entity1 with the @entity5337 mutation who are undergoing hip or knee joint replacement surgery and are receiving effective antithrombotic prophylaxis.
